Circulating PCSK9 levels are not associated with the conversion to type 2 diabetes.
作者： Stéphane Ramin-Mangata , Matthieu Wargny , Matthieu Pichelin , Cédric Le May , Aurélie Thédrez
DOI: 10.1016/J.ATHEROSCLEROSIS.2019.11.027
关键词:
摘要: … In conclusion, this study assessed for the first time the association between circulating PCSK9 levels and the risk of diabetes in longitudinal analyses. Our data indicates that …
sci-hub.se 参考文章(50)
Payal Kohli, David D. Waters, Rita Nemr, Benoit J. Arsenault, Michael Messig, David A. DeMicco, Rachel Laskey, John J.P. Kastelein, Risk of new-onset diabetes and cardiovascular risk reduction from high-dose statin therapy in pre-diabetics and non-pre-diabetics: an analysis from TNT and IDEAL. Journal of the American College of Cardiology. ,vol. 65, pp. 402- 404 ,(2015) , 10.1016/J.JACC.2014.10.053
Bertrand Cariou, Maëlle Le Bras, Cédric Langhi, Cédric Le May, Béatrice Guyomarc’h-Delasalle, Michel Krempf, Philippe Costet, Association between plasma PCSK9 and gamma-glutamyl transferase levels in diabetic patients Atherosclerosis. ,vol. 211, pp. 700- 702 ,(2010) , 10.1016/J.ATHEROSCLEROSIS.2010.04.015
C. R. Dormuth, K. B. Filion, J. M. Paterson, M. T. James, G. F. Teare, C. B. Raymond, E. Rahme, H. Tamim, L. Lipscombe, , Higher potency statins and the risk of new diabetes: multicentre, observational study of administrative databases BMJ. ,vol. 348, ,(2014) , 10.1136/BMJ.G3244
Liam R Brunham, Janine K Kruit, Terry D Pape, Jenelle M Timmins, Anne Q Reuwer, Zainisha Vasanji, Brad J Marsh, Brian Rodrigues, James D Johnson, John S Parks, C Bruce Verchere, Michael R Hayden, β-cell ABCA1 influences insulin secretion, glucose homeostasis and response to thiazolidinedione treatment Nature Medicine. ,vol. 13, pp. 340- 347 ,(2007) , 10.1038/NM1546
Cédric Langhi, Cédric Le May, Valéry Gmyr, Brigitte Vandewalle, Julie Kerr-Conte, Michel Krempf, François Pattou, Philippe Costet, Bertrand Cariou, PCSK9 is expressed in pancreatic δ-cells and does not alter insulin secretion Biochemical and Biophysical Research Communications. ,vol. 390, pp. 1288- 1293 ,(2009) , 10.1016/J.BBRC.2009.10.138
Christian Werner, Michael M. Hoffmann, Karl Winkler, Michael Böhm, Ulrich Laufs, Risk prediction with proprotein convertase subtilisin/kexin type 9 (PCSK9) in patients with stable coronary disease on statin treatment. Vascular Pharmacology. ,vol. 62, pp. 94- 102 ,(2014) , 10.1016/J.VPH.2014.03.004
Gilles Lambert, Barbara Sjouke, Benjamin Choque, John J. P. Kastelein, G. Kees Hovingh, The PCSK9 decade. Journal of Lipid Research. ,vol. 53, pp. 2515- 2524 ,(2012) , 10.1194/JLR.R026658
M.C.G.J. Brouwers, J.S. Troutt, M.M.J. van Greevenbroek, I. Ferreira, E.J. Feskens, C.J.H. van der Kallen, N.C. Schaper, C.G. Schalkwijk, R.J. Konrad, C.D.A. Stehouwer, Plasma proprotein convertase subtilisin kexin type 9 is not altered in subjects with impaired glucose metabolism and type 2 diabetes mellitus, but its relationship with non-HDL cholesterol and apolipoprotein B may be modified by type 2 diabetes mellitus: The CODAM study Atherosclerosis. ,vol. 217, pp. 263- 267 ,(2011) , 10.1016/J.ATHEROSCLEROSIS.2011.03.023
Qin Cui, Xianxia Ju, Tao Yang, Mei Zhang, Wei Tang, Qi Chen, Yong Hu, Joseph V. Haas, Jason S. Troutt, Richard T. Pickard, Ryan Darling, Robert J. Konrad, Hongwen Zhou, Guoqing Cao, Serum PCSK9 is associated with multiple metabolic factors in a large Han Chinese population Atherosclerosis. ,vol. 213, pp. 632- 636 ,(2010) , 10.1016/J.ATHEROSCLEROSIS.2010.09.027
P. Costet, M.M. Hoffmann, B. Cariou, B. Guyomarc’h Delasalle, T. Konrad, K. Winkler, Plasma PCSK9 is increased by Fenofibrate and Atorvastatin in a non-additive fashion in diabetic patients Atherosclerosis. ,vol. 212, pp. 246- 251 ,(2010) , 10.1016/J.ATHEROSCLEROSIS.2010.05.027